TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of women diagnosed with advanced breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Reduced Sexual Risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased Condom Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced Alcohol and Illicit Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced Violence and Victimization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in modulation of the biomarker phospho-Akt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline PainDETECT Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Level of Health Clinic Stigma and Discrimination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Number of AGYW who Uptake HIV and SRH services, including PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Initiation of the HPV 2-dose series
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of the HPV 2-dose series
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: breast cancer response to neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Condomless Sex
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of Substance Use
Endpoint domain: Adverse events/effects
Primary endpoint: compatibility of the skin with the new formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: recurrence of atopic eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of disease flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Pathologic Response (pCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional skin closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Body mass index (BMI) >= 85th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of Pathological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean carotid IMT difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean change in glucose area under curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major adverse cerebral and cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Persistent mastectomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of expression of PD-L1+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Continence status in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise adherence and performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parent Prematurity Knowledge Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Preparation for Decision Making Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tolerability profiles
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall cost of patient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Boezaart surgical grading scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from AF/AFL/AT off antiarrhythmic drugs therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident rates of BPAR (Biopsy-Proven Acute Rejection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incident rates of DGF (Delayed Graft Function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relative Phosphorylation of ERBB2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Sustained Objective Response (Complete or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control (mean 24-hour and nocturnal glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Periprosthetic Joint Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Disease Activity Score Based on 28-joints Count (DAS28) at Month 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Month 60
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Relapse-free at Month 6
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with pulmonary relapse detected by ultra-low-dose CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with pulmonary relapse detected by chest x-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with pulmonary relapse by symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: End Tidal Carbon Dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Growth (weight, length and head circumference)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity (serious adverse events, hospital re-admissions)
Endpoint domain: Adverse events/effects
Primary endpoint: Development (mental, motor, visual and language)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of insulin acceptance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of insulin initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient satisfaction with counselors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction with counseling session
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction with clinic experience overall
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short-term outcome assessed by AgeWise battery of assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of BBTI evaluated by clinical portions of Agebat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotype of compliant or not compliant patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Minimum 2-grade Improvement in ISGA Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-op Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Exposure (AUC) after microdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative sensitivity and specificity of PET scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with vaginitis
Endpoint domain: Adverse events/effects
Primary endpoint: # of participants with all AEs as assessed by CTCAE V4.0
Endpoint domain: Adverse events/effects
Primary endpoint: 12 lead electrocardiogram parameters (PR, QTcF, QTcB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical chemistry, haematology, urinalysis, liver function tests (ALT, AST, GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height, weight, blood pressure, heart rate, respiration rate and temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tibio-femoral contact points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of dry eye syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regulatory T cell induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrence of AK Lesions
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetics of total plasma temocillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of unbound plasma temocillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Perceived Continuity of Care From Multiple Providers - Management Continuity
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient Perceived Continuity of Care From Multiple Clinicians - Informational Continuity
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Patient Perceived Continuity of Care From Multiple Clinicians - Role Continuity
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Performance of multi-marker panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in spinal cord metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in circulating MGP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin microvascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tumor measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC0-12weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7 Day Point Prevalence Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous Abstinence From Smoking Since Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Smoking Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reintubation within 72 hours from extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccine-related Grade 3 or 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical PSA response
Endpoint domain: Physiological/clinical
Primary endpoint: Antibiotics prescription for UTI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to First Alleviation of Influenza Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' experiences of symptoms related to parastomal bulging
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of laser ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Unanticipated Device- or Drug-Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Forwarded the Video
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma levels of markers of endothelial activation and vascular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ability to achieve good quality retinal images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to achieve imaging without causing pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Urine Protein Creatinine Ratio (UPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Symptom and Medication Score (SMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of cytology with concordant colposcopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-interval intracortical inhibition (LICI) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Tympanic Membrane Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interferon-stimulated-gene (ISG) Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of hand dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of oocyte retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in CD4+ T Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adverse neonatal outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: volatile compound concentrations in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: metabolite concentrations in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fecal calprotectin (µg/g) in fecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean 24-hour Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnosis of anastomotic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to graft reepithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score higher than or equal to 21 of the erectile dysfunction domain of the IIEF
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Response to treatment
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Affirmative response to the GAQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerance of rectal endometriosis treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPAP Therapy Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of systemic signs of scorpion envenomation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite prevalence of desaturation (SPO2 < 95%) or Bradycardia (HR <60 beats per minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Safety Laboratory Tests at Least Once Post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Meet Markedly Abnormal Criteria, for Vital Sign Measurements at Least Once Post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Meet the Markedly Abnormal Criteria, for Electrocardiogram (ECG) Measurements at Least Once Post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: WOMET Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gait Knee Adduction Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average Rotation During Stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum observed plasma concentration of GLPG1690 (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity of GLPG1690 (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life of GLPG1690 (t1/2,λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation Rate of Statin Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Statin-related Myalgia
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Satisfaction With Telehealth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: T-cell IFN-γ response to the Leish-111f protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of successful abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants With rSBA Titers >= 1:8 and >=1:128
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titers With rSBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Observer Agreement Between Bone Age Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of contractions to onset of claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: time to intolerable claudication pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of fetal weight estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of acute and chronic GVHD requiring treatment
Endpoint domain: Adverse events/effects
Primary endpoint: degree of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion rate from therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in neurosensory function of inferior alveolar nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in facial gingival profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient comfort during CTR
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate: Proportion of patients with reduction of viral load to < 50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Corticomotor Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: radiological incisional hernia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: All-cause Mortality Rate at Day 14
Endpoint domain: Mortality/survival
Primary endpoint: Time to first event of all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Time to first event of unplanned hospitalization for worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of ventricular and cisternal clot clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ADAS-cog+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Quality control in primary care spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Anti-platelet agent discontinuation/interruption/disruption
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major and minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of definite and/or probable stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in reduction of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Level of IHC-Ki-67 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in temporalspatial components of Gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes